Biomarin Pharmaceutical Inc. (BMRN)
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why
BioMarin (BMRN) could produce exceptional returns because of its solid growth attributes.
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
BioMarin Pharmaceutical Inc. BMRN announced an update on its Roctavian business to focus commercial operations on three markets: the U.S., Germany and Italy.
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.
BioMarin: Q2 Revenue Soars 20%
Revenue for Q2 2024 totaled $712 million, a 20% year-over-year increase. Management raised full-year 2024 guidance, reflecting the company's optimistic outlook.
BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2024 Results Conference Call August 5, 2024 5:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and Chief Executive Officer Hank Fuchs - President, Worldwide Research & Development Brian Mueller - Executive Vice President, Chief Financial Officer Cristin Hubbard - Executive Vice President, Chief Commercial Officer Conference Call Participants Phil Nadeau - TD Cowen Salveen Richter - Goldman Sachs Ellie Merle - UBS Cory Kasimov - Evercore Jessica Fye - JPMorgan Paul Matteis - Stifel Joseph Schwartz - Leerink Partners Chris Raymond - Piper Sandler Gena Wang - Barclays Kostas Biliouris - BMO Capital Markets Mohit Bansal - Wells Fargo Olivia Brayer - Cantor Fitzgerald Luca Issi - RBC Capital Operator Good afternoon, and welcome to the BioMarin Pharmaceuticals Second Quarter 2024 Conference Call. Please note that this call is being recorded.
BioMarin (BMRN) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.96 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.54 per share a year ago.
Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings
Evaluate the expected performance of BioMarin (BMRN) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Why BioMarin (BMRN) is Poised to Beat Earnings Estimates Again
BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is The Options Market Predicting A Spike In BioMarin Pharmaceutical (BMRN) Stock?
Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.
Beacon Pointe Advisors LLC Sells 133 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Beacon Pointe Advisors LLC lessened its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,838 shares of the biotechnology company’s stock after selling 133 shares during the period. Beacon Pointe Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $1,720,000 at the end of the most recent reporting period. A number of other institutional investors have also recently modified their holdings of the stock. Barclays PLC increased its stake in BioMarin Pharmaceutical by 31.6% in the third quarter. Barclays PLC now owns 5,573,157 shares of the biotechnology company’s stock valued at $493,111,000 after acquiring an additional 1,336,886 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of BioMarin Pharmaceutical by 5.6% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,163,949 shares of the biotechnology company’s stock valued at $456,906,000 after purchasing an additional 275,436 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of BioMarin Pharmaceutical by 5.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,378,897 shares of the biotechnology company’s stock worth $132,953,000 after buying an additional 74,100 shares in the last quarter. Fort Washington Investment Advisors Inc. OH lifted its position in shares of BioMarin Pharmaceutical by 10.7% during the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 1,308,245 shares of the biotechnology company’s stock worth $115,754,000 after buying an additional 126,680 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in BioMarin Pharmaceutical by 3.7% in the third quarter. Northern Trust Corp now owns 1,219,814 shares of the biotechnology company’s stock valued at $107,929,000 after buying an additional 43,695 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors. BioMarin Pharmaceutical Trading Up 0.8 % NASDAQ BMRN opened at $77.56 on Monday. BioMarin Pharmaceutical Inc. has a 52 week low of $76.02 and a 52 week high of $99.56. The business has a 50 day moving average price of $85.47 and a 200-day moving average price of $88.90. The company has a quick ratio of 1.70, a current ratio of 2.74 and a debt-to-equity ratio of 0.12. The company has a market cap of $14.73 billion, a price-to-earnings ratio of 72.49, a P/E/G ratio of 1.22 and a beta of 0.34. BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.12. The firm had revenue of $648.83 million for the quarter, compared to the consensus estimate of $649.75 million. BioMarin Pharmaceutical had a net margin of 8.31% and a return on equity of 5.34%. As a group, equities analysts expect that BioMarin Pharmaceutical Inc. will post 1.99 earnings per share for the current fiscal year. Insiders Place Their Bets In related news, Director Jean Jacques Bienaime sold 1,000 shares of the company’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $90.35, for a total transaction of $90,350.00. Following the completion of the sale, the director now owns 562,203 shares in the company, valued at $50,795,041.05. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Jean Jacques Bienaime sold 1,000 shares of BioMarin Pharmaceutical stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $90.35, for a total transaction of $90,350.00. Following the sale, the director now directly owns 562,203 shares in the company, valued at approximately $50,795,041.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Erin Burkhart sold 2,286 shares of BioMarin Pharmaceutical stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $90.00, for a total transaction of $205,740.00. Following the completion of the sale, the chief accounting officer now directly owns 16,156 shares in the company, valued at approximately $1,454,040. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,079 shares of company stock valued at $9,528,436. Corporate insiders own 1.85% of the company’s stock. Wall Street Analyst Weigh In Several equities analysts recently commented on BMRN shares. Citigroup dropped their price objective on shares of BioMarin Pharmaceutical from $94.00 to $91.00 and set a “neutral” rating for the company in a research note on Thursday, April 25th. Robert W. Baird cut BioMarin Pharmaceutical from an “outperform” rating to a “neutral” rating and dropped their price target for the company from $104.00 to $72.00 in a research note on Friday. Piper Sandler reduced their price objective on BioMarin Pharmaceutical from $115.00 to $107.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Scotiabank upped their target price on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the stock a “sector perform” rating in a report on Thursday, April 25th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $110.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, April 25th. Nine investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average target price of $106.11. View Our Latest Research Report on BMRN BioMarin Pharmaceutical Company Profile (Free Report) BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
